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ABSTRACT
DNA methylation changes that are recurrent in
cancer have generated great interest as potential
biomarkers for the early detection and monitoring of
cancer. In such situations, essential information is
missed if the methylation detection is purely quali-
tative. We describe a new probe-free quantitative
methylation-specific PCR (MSP) assay that incorpo-
rates evaluation of the amplicon by high-resolution
melting (HRM) analysis. Depending on amplicon
design, different types of information can be
obtained from the HRM analysis. Much of this
information cannot be obtained by electrophoretic
analysis. In particular,identification offalse positives
due to incomplete bisulphite conversion or false
priming is possible. Heterogeneous methylation can
also be distinguished from homogeneous methyla-
tion. As proof of principle, we have developed assays
for the promoter regions of the CDH1, DAPK1,
CDKN2A (p16
INK4a) and RARB genes. We show that
highly accurate quantification is possible in the
range from 100% to 0.1% methylated template
when 25ng of bisulphite-modified DNA is used as a
templateforPCR.Wehavenamedthisnewapproach
to quantitative methylation detection, Sensitive
Melting Analysis after Real Time (SMART)-MSP.
INTRODUCTION
In mammalian cells, DNA methylation occurs almost
exclusively at the carbon-5 position of cytosine residues
within CpG dinucleotides. The CpG dinucleotide is
distributed in a non-random fashion throughout the
human genome. CpG-depleted regions are interspersed
with CpG-rich sequences referred to as CpG islands (1).
These islands are often located at promoter regions of
protein encoding genes and tend to be unmethylated (2,3).
Aberrant DNA methylation patterns are one of the
hallmarks of cancer. In most cancers, promoter hyper-
methylation correlates with gene silencing. This has been
shown for a wide range of tumour suppressor genes
including the genes studied here and reviewed in (2,3):
the cell-cycle inhibitor gene CDKN2A (p16
INK4a), the pro-
apoptotic death-associated protein kinase gene DAPK1,
the cell-adhesion gene CDH1 and the retinoic acid
receptor gene RARB.
In cancer, methylation of some promoter CpG islands
can be an early event, and thus the detection of methyl-
ation shows great promise as a biomarker for early
detection (4–6). Conventional methods for cancer detec-
tion are in general not capable of ﬁnding pre-neoplastic
and small malignant lesions, and are thus not suitable for
early detection. Molecular biomarkers in body liquids
such as blood, sputum or urine that allow detection and
diagnosis of tumours at an early stage would be ideal.
However, in these types of samples, tumour-derived
material is hard to detect because of the presence of
material from normal cells, and thus highly sensitive
methods are needed (7). As one example, methylation of
the CDKN2A promoter has been detected in the sputum
of smokers up to 3 years before they are diagnosed with
cancer (8). Detection of low level methylation also shows
great potential in the molecular monitoring of established
disease after therapy (4). This has already been shown to
be feasible in various cancers using DNA derived from
plasma or serum (9,10).
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tive method for the detection of low level methylation, and
can be sensitive to at least 0.1% methylated template.
However, MSP is prone to false-positive results (12–14).
MSP primers are normally designed to have one or more
cytosines of CpG sites at or near the 30 end. This makes
the primers highly selective for methylated template, but
also facilitates ampliﬁcation of incompletely converted
sequences in the bisulphite-treated DNA (13). It is thought
that bisulphite treatment, in spite of recent improvements
in this area, still remains the main source of variability in
the analysis of DNA methylation. Recent results show
that incomplete conversion may typically be in the order
of 2%, even when a commercial kit is used (15,16). This
variability can not only lead to false-positive results, but
can also impair quantitative assays in a way that leads to
overestimation of methylation levels (17), especially when
looking at low level methylation.
Diﬀerent methods for the detection of incompletely
converted products co-ampliﬁed during the PCR have
been proposed (14,16,18). These methods are relatively
labour intensive and require removal of the PCR product
from the tube for further analysis creating the potential
for PCR contamination, or the use of additional probes as
in the ConLight-MSP methodology (14).
MSP has been made quantitative by the use of
ﬂuorescent TaqMan probes enabling real time detection
of MSP products (such as in the MethyLight technique)
(19–21). This also eliminates any signal from non-speciﬁc
ampliﬁcation. However, the introduction of a probe com-
plicates assay design, and can result in heterogeneously
methylated sequences that would otherwise be detected by
MSP being missed, because of the need for the probe to
hybridize correctly before a signal is observed.
Here we present a new method: Sensitive Melting
Analysis after Real Time (SMART)-MSP for sensitive
DNA methylation detection based on probe-free real-time
PCR. With the use of a new generation of ﬂuorescent
dyes, which do not inhibit PCR when they intercalate
into double-stranded DNA at saturating levels (22),
highly accurate quantiﬁcation and further analysis of the
amplicon by high-resolution melting (HRM), has become
possible. As the temperature increases during the HRM
step, and the DNA ‘melts’, the dye is released and the
signal of ﬂuorescence decreases rapidly. This change in
ﬂuorescence is sequence speciﬁc and can be monitored by
appropriately designed instrumentation.
SMART-MSP provides information that cannot be
obtained by electrophoresis, and thus functions as a
quality control to avoid false-positive results caused by
incomplete conversion or false priming due to less
stringent PCR conditions. Primer dimers and non-speciﬁc
products can be detected as well.
We developed SMART-MSP assays for several tumour
suppressor genes that are currently used as molecular
biomarkers for early cancer detection or are likely to have
a high potential as such. The quantitative accuracy of the
assays was tested using a standard dilution series of
methylated DNA into unmethylated DNA. Furthermore,
we show that false-positive results due to incomplete
bisulphite conversion or false priming can be identiﬁed by
HRM analysis and we have analysed a panel of cell
lines, and breast cancer samples by the SMART-MSP
methodology.
MATERIALS AND METHODS
Samples and DNA extraction
The investigations were performed after approval by the
Peter MacCallum Cancer Centre Ethics of Human
Research committee (Projects 02/70 and 02/26). Puriﬁed
genomic DNA from cell lines (2008, MCF7, HS578T,
MCF10A, MDA-MB-468, MDA-MB-231, MDA-MB-
435, PC3, SKBr-3, Colo205, RPMI8226, SW948, HL-60
and T47D) was available in our laboratory. The DNA was
extracted using the QIAamp DNA Blood Mini Kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. Breast cancer samples were provided
by the Peter MacCallum Cancer Centre Tissue Bank.
DNA from those samples was extracted using the salting
out method (23). Universal Methylated DNA (Chemicon,
Millipore, Billerica, MA, USA) was used as a fully
methylated positive control. DNA from peripheral blood
mononuclear cells from normal individuals was used
as unmethylated DNA for dilutions. Standard dilution
series of 100, 10, 1, 0.1 and 0.01% methylation levels were
prepared by diluting the fully methylated DNA into
the unmethylated DNA. DNA was quantiﬁed with a
NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA).
Whole-genome amplification
Whole-genome ampliﬁcation (WGA) was performed as
described by Umetani et al. (24) with slight modiﬁcations.
Brieﬂy, for primary WGA, 1ng of genomic DNA extrac-
ted from peripheral blood mononuclear cells in 1ml was
subjected to ampliﬁcation (2h at 308C) with the Illustra
GenomiPhi V2 DNA Ampliﬁcation Kit (GE Healthcare,
Little Chalfont, UK) according to the manufacturer’s
instructions. For secondary WGA, 0.1ml of the unpuriﬁed
primary WGA product was diluted in water to a ﬁnal
volume of 1ml and processed as described above. The
secondary WGA product was puriﬁed using the
QIAquick PCR Puriﬁcation Kit (Qiagen) according to
the manufacturer’s instructions, eluted in 50ml buﬀer EB,
and quantiﬁed with a NanoDrop ND-1000 spectro-
photometer. The secondary WGA product was used as
fully unmethylated DNA (negative control).
Bisulphite modification
Five hundred nanograms of genomic DNA or WGA
product was subjected to bisulphite conversion with the
EpiTect Bisulﬁte kit (Qiagen) according to the manu-
facturer’s instructions. The puriﬁed, bisulphite-modiﬁed
DNA (WGA product) was eluted two times in 20ml buﬀer
EB. Incomplete bisulphite-modiﬁed DNA was prepared
by treating the appropriate samples for 20 or 40min
with the bisulphite mix solution and puriﬁed as described
earlier.
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The primers were designed to include at least two CpG
sites, and one of the cytosines of a CpG site was always
placed at or adjacent to the 30 end. This will make the
primers as selective for methylated templates as possible,
and ensure that only these are ampliﬁed during PCR if
suﬃciently stringent conditions are chosen. Non-CpG
cytosines were included in the primer sequences as well to
select against incompletely converted sequences, and at
least one of these was placed as close to the 30 end as
possible. Primer Express 1.5 (Applied Biosystems, Foster
City, CA, USA) was used to calculate the estimated
annealing temperature of the primers. Amplicons were
designed to have only one melting domain according
to the POLAND software (http://www.biophys.uni-
duesseldorf.de/local/POLAND/poland.html) (25). The
program Amplify (http://engels.genetics.wisc.edu/amplify/)
was used to check for primer dimers, and no single
nucleotide polymorphisms (SNPs) were found in any of
the designed amplicons using BLAST searching of the
SNP database (dbSNP BUILD 127). This is important
since SNPs will interfere with the melting proﬁle (if found
in between primers) or possibly aﬀect primer binding. The
primer sequences and genomic regions spanned, as well as
amplicon size and the annealing temperatures (TA) can be
found in Table 1.
PCR and HRM conditions fortheSMART-MSP assays
PCR cycling and HRM analysis were performed on the
Rotor-Gene 6000
TM (Corbett Research, Mortlake,
Australia). SYTO 9 was used as the intercalating dye
(Invitrogen, Carlsbad, CA, USA). The reaction mixtures
consisted of 25ng of bisulphite-modiﬁed template (the-
oretical amount), 1x PCR buﬀer, 2.5mmol/l MgCl2 ﬁnal
(3mmol/l in the CDH1 assay), 200nmol/l of each primer,
200mmol/l of each dNTP, 5mmol/l of SYTO 9, 0.5 U of
HotStarTaq (Qiagen) (5U/ml) in a ﬁnal volume of 20ml.
The cycling protocol started with one cycle of 958C for
15min for enzyme activation, followed by 45 cycles of
958C for 20s, annealing at the appropriate temperature
(Table 1) for 30s, 728C for 30s and one cycle of 958C for
1min. HRM was performed from 608Ct o9 0 8C, with a
temperature increase at the rate of 0.28C/s for all assays.
The annealing temperature was experimentally determined
for each assay to ensure that only methylated templates
were ampliﬁed. For each assay, a standard dilution series
was run to assess the quantitative properties and
sensitivity of these. Fully methylated and fully unmethyl-
ated control (WGA product), unmodiﬁed control and
no template control were also included in every run. All
samples were analysed in triplicate and each breast
tumour sample in duplicate.
Gel electrophoresis analysis
Five microlitres of the PCR products were resolved on
2.5% agarose gels and stained with ethidium bromide.
The CDH1 and RARB MethyLight assays
The same primers were used for the MethyLight assays as
for the SMART-MSP assays. The probe sequences were
FAM-50-ttcgcgttgttgattgg-30-BHQ for CDH1 and FAM-
50-ttgggtatcgtcggggta-30-BHQ for RARB. The reaction
mixtures consisted of 25ng of bisulphite-modiﬁed DNA
(theoretical amount), 1x PCR buﬀer, 250nmol/l of probe,
3mmol/l MgCl2, 200nmol/l of each primer, 200mmol/l of
each dNTP, and 0.5U of HotStarTaq (Qiagen) (5U/ml)
in a total volume of 20ml. The cycling protocol started
with one cycle of 958C for 15min, followed by 45 cycles of
958C for 20s and 638C (648C in the CDH1 assay) for 40s.
PCR cycling was performed on the Rotor-Gene 6000. All
samples were analysed in triplicate and each breast
tumour sample in duplicate.
Realtime PCR quantification
The relative 2
( CT) quantiﬁcation approach (26) was
used. The cycle threshold (CT) value of the control
COL2A1 assay (Table 1) is subtracted from the CT value
of the target gene for the calibrator sample, the 100%
methylated standard. For each test sample, this value is
then subtracted from the value resulting from the CT value
of the target gene minus the CT value for the COL2A1
control assay. This gives the ‘
CT’ value, which is then
put in to the equation, 2
( CT), and multiplied by 100 to
give the percentage of methylation relative to the 100%
methylated control. For this approach to be valid, the
ampliﬁcation eﬃciencies of the gene and the control must
Table 1. Primer sequences, annealing temperatures, and amplicon information for the SMART-MSP assays (UCSC Genome Browser,
November 2007)
Gene Primer sequences (CpG sites in
bold and converted Cs as
capital Ts or As)
Annealing
temperature
(8C)
Amplicon
size (bp)
CpGs/non-CpG-Cs
between the primers
Spanned region
CDH1 F-gtgggcgggTcgtTagTtTc 64 86 2/8 67328555-67328640 of Chr. 16
R-cgctAattAActAaAAAttcacctAccg
DAPK1 F-aggaTagTcggaTcgagTTaacgTc 67 61 0/4 89302618-89302678 of Chr. 9
R-ttAccgaAtcccctccgcgA
CDKN2A F-gTaTTtTTtTcgagTaTtcgTtTacggc 63 72 0/6 21964971-21965042 of Chr. 9
R-caaatcctctAAaAAAaccgcgA
RARB F-TcgagaacgcgagcgatTc 63 146 5/18 25444864-25445008 of Chr. 3
R-gAccaatccaAccgAAAcg
COL2A1 F-gTaatgTTaggagTaTTTtgtgggTa 65 86 0/1 46667210-46667295 of Chr. 12
R-ctaccccaAAaAaAcccaAtcctA
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comparative quantiﬁcation (a feature of the Rotor-Gene
6000 Series Software, version 1.7.61) were used as CT
values in the calculations. The take-oﬀ point is deﬁned as
the cycle at which the second derivative is at 20% of the
maximum level, which indicates the end of the back-
ground noise and the transition into the exponential
phase.
RESULTS
The basis ofSMART-MSP
Real-time ampliﬁcation of bisulphite-converted DNA
with MSP primers is performed with a ﬂuorescent dye,
which does not inhibit the PCR when used at saturat-
ing conditions (22). This allows for highly accurate
quantitative results to be obtained without the use of
probes and for HRM analysis to be performed.
Quantiﬁcation is based on CT values, and thus it is
necessary to run a control assay in parallel to normalize
for the amount of input DNA in the PCR. We designed
a new COL2A1 control assay to estimate the amount of
ampliﬁable template (Table 1), adjacent to the region used
previously as an input control in MethyLight-based assays
(27). The region we chose has improved selection against
the ampliﬁcation of unconverted DNA (data not shown).
In the SMART-MSP methodology, sensitive melting
analysis using HRM is performed immediately after the
real-time PCR in a closed-tube system. The kind of
information that can be obtained from HRM is dependent
on amplicon design, and should be interpreted by
considering the ampliﬁcation data as well (Figure 1).
First, when only non-CpG cytosines are included in
Region in between primers
Non-CpG cytosines CpG (and non-CpG) cytosines Comments
Melting profile
(theoretical)
Amplification Melting profile
(theoretical)
Amplification
* Fully methylated template
will amplify early relative
to a heterogeneously
methylated template.  However,
late amplification is observed
when the percentage of fully
methylated template is low. N
Full methylation
Heterogeneous
methylation
N
N
N (       )
Incomplete
conversion
Unmethylated
(false priming)
M (       )‡ 
M (       )§
M
M†
Early * Early *
† In this situation,a complex
melting pattern composed of
heteroduplexes as well as
homoduplexes will generally
occur. The more CpGs in
between the primers, the more
complex the pattern.
Intermediate
to late
Intermediate
to late
‡ A single left-shifted melting
peak is an indication that all
the CpGs in between the
primers were unmethylated,
and thus amplification may be 
a result of false priming.
Very late Very late
§ If non-CpG cytosines are
included a right-shifted melting
profile may be observed,
dependent on the methylation
status of the CpG cytosines in
between the primers. This can
be complex to interpret.
Late Late
Figure 1. A schematic overview of SMART-MSP. Bisulphite-modiﬁed DNA is ampliﬁed in real time using a HRM-compatible intercalating dye to
obtain quantitative data. After real-time PCR a HRM step is performed for quality control of the amplicon. The interpretation is made by
considering both the real-time PCR and the HRM information. Two diﬀerent types of SMART-MSP amplicon design are shown here, in
combination with the melting proﬁles and ampliﬁcation data that can be expected (vertical rows), in diﬀerent methylation and conversion situations
(horizontal rows). Incomplete conversion can be detected most readily when non-CpG cytosines are found in between the primers and no CpG
cytosines are found. By including CpG cytosines in between the primers, it can be determined if the region is heterogeneously methylated or
unmethylated. If the CpG cytosines in between the primers are unmethylated, the ampliﬁcation might be a result of false priming. N and M are
theoretical temperatures dependent on the amplicon size and sequence.
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control for ampliﬁcation of incompletely converted DNA.
If incomplete converted sequences are ampliﬁed, the
amplicon will have a higher GC-content relative to fully
converted amplicons, and will therefore melt later.
We designed the DAPK1 and CDKN2A assays in this way.
Second, when CpG sites are included between the
primers, the HRM step can be used to assess if these CpG
sites are methylated. We designed the CDH1 and RARB
assays in this way. Generally, if left-shifted melting is
observed, this is an indicator that some or all of the CpG
sites are not methylated. A complex melting pattern
consisting of heteroduplexes as well as homoduplexes can
occur if more than one molecule is ampliﬁed during the
PCR and the studied region is heterogeneously methy-
lated. Thus, a heterogeneously methylated region can give
a melting proﬁle extending to the left, due to the melting
of molecules with diﬀerent CpG positions being methyl-
ated and heteroduplex formation between them (Figure 1).
Left shifting can also indicate false positives due to
false priming. In this case, a single left-shifted peak will be
seen. Generally, false priming is associated with very late
ampliﬁcation (Figure 1). False priming can generally be
minimized by stringent PCR conditions. Assays should be
designed to include as few non-CpG cytosines as possible,
preferably none. A conversion control should be per-
formed in parallel when non-CpG cytosines cannot be
avoided to be conﬁdent that these are converted. Our
CDH1 and RARB primers were designed so that they can
also be used with a MethyLight probe for validation of
the SMART-MSP methodology. Because of this, more
non-CpG cytosines are found in between the primers
than what would be ideally preferred. Generally, longer
products give more intrinsic variation of the melting
curves (unpublished results).
Third, small amplicons can be designed that do not
include non-CpG cytosines or CpG sites. In this case, only
the methylation status of those CpG sites found under the
primers are assessed, and the HRM step is used only then
to validate that the correct sequence is ampliﬁed.
In all the above cases, the presence of primer dimers
and non-speciﬁc products can be identiﬁed on the basis
of aberrant melting proﬁles by HRM analysis (data not
shown) without the need for gel electrophoresis.
Melting profiles of theSMART-MSP assays
The melting proﬁles of a true positive result, obtained by
amplifying standards containing methylated template for
each assay, were used as references for unknown samples
(Figure 2). Since all the ampliﬁed dilution standards for
a given amplicon have the same melting proﬁle, we could
have chosen any one of them as a reference. The melting
temperature of each assay was approximately 83.28C for
CDH1, 79.58C for DAPK1, 75.88C for CDKN2A and
80.88C for RARB. Conﬁrmatory gel electrophoresis was
performed in the development phase for all assays, and
only one band of the expected size was observed (data not
shown).
Figure 2. Melting proﬁles of a true positive result for each SMART-MSP assay. Universally methylated template was ampliﬁed and analysed
by HRM analysis. Each assay has a characteristic melting proﬁle. (A) The CDH1 assay. (B) The DAPK1 assay. (C) The CDKN2A assay.
(D) The RARB assay.
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SMART-MSP assays
Each SMART-MSP assay was optimized so that ampli-
ﬁcation only occurred from standards containing methyl-
ated template, and no ampliﬁcation was seen in the fully
unmethylated control (WGA product), in the unmodiﬁed
control or in the no template control. The sensitivity and
quantitative accuracy of the assays were determined using
the standard dilution series (see Materials and methods
section). All our assays were able to reliably detect the
0.1% methylated standards (Figure 3).
The quantitative accuracy of each assay was determined
using the relative 2
( CT) quantiﬁcation approach (see
Materials and methods section). Ampliﬁcation eﬃciencies
of the gene and the control were approximately equal for
all assays (data not shown). The calculated values for each
standard were plotted versus the dilution factor for each
gene (Figure 4).
All reactions contained approximately equal amounts
of template suitable for PCR. This was evident from the
similar CT values obtained in the control assays (data not
shown). We used the software to obtain a standard curve
for the dilution series for calculation of the correlation
coeﬃcient (r
2) for each assay. The correlation coeﬃcient
for each assay (DAPK1: r
2=0.995, CDKN2A: r
2=0.998,
CDH1: r
2=0.999, RARB: r
2=0.995) indicated a strong
linear relationship between CT values and given concen-
trations for all assays.
We also tested the CDH1 and RARB MethyLight
assays. These MethyLight assays were quantitatively
accurate in the range from 100% down to 0.1% methyl-
ated template. The correlation coeﬃcients of the
MethyLight assays were: CDH1: r
2=0.984 and RARB:
r
2=0.983, again indicating a strong linear relationship
between CT values and given concentrations for both.
Validation of theDAPK1 andCDKN2A SMART-MSP
conversion control assays
Bisulphite conversion can be assessed by HRM analysis
using assays with non-CpG cytosines between the primers.
If a right shift of the melting proﬁle is observed, this can
only be due to incomplete conversion of some or all of the
non-CpG cytosines in between the primers or ampliﬁca-
tion of non-speciﬁc products (Figure 1). Since incom-
pletely converted products are of the same size as true
positives, these cannot be distinguished using gel electro-
phoresis. We generated incompletely converted DNA (see
Materials and methods section) to assess whether its
ampliﬁcation showed right-shifted melting proﬁles in these
assays. Ampliﬁcation was usually seen from these samples
and always showed right-shifted melting proﬁles. As
expected, the 100% methylated standard ampliﬁed earlier
than incompletely converted DNA in both assays, and
thus gave higher melting peaks (Figure 5).
We showed that bisulphite-modiﬁed template melts
early relative to unmodiﬁed template (Figure 6). A primer
pair (50-gggaagatgggatagaagggaataT and 50-tctAacaAttA
tAAActccaaccaccaa) with a limited number of non-CpG
cytosines in their sequences (shown in upper case), and
thus not particularly discriminatory against unmodiﬁed
sequences, was used to amplify bisulphite-modiﬁed as well
as unmodiﬁed DNA from the same sample. In this assay,
ﬁve non-CpG cytosines and no CpG sites are found in
between the primers. Since the unmodiﬁed amplicon has a
Figure 3. The sensitivity of the SMART-MSP assays. In all assays, the 0.1% methylated standard could be detected with high reproducibility.
(A) The CDH1 assay. (B) The DAPK1 assay. (C) The CDKN2A assay. (D) The RARB assay.
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the bisulphite-modiﬁed amplicon.
Identification offalse positives inthe CDH1
SMART-MSP assay
By running the CDH1 SMART-MSP assay for an
additional 10 cycles, late ampliﬁcation from the fully
unmethylated control (WGA product) occurred. Since this
WGA control is not methylated at the two CpG sites
in between the primers, we expected to see a readily
distinguishable left-shifted melting peak, and thus to be
able to identify it as a false-positive result (Figure 1). The
melting peak of the unmethylated control (WGA product)
was shifted  1.28C to the left compared to the standards
containing methylated template (Figure 7).
Screening of cell lines
The reliability of our method was tested using a panel of
14 cell lines (2008, MCF7, HS578T, MCF10A, MDA-
MB-468, MDA-MB-231, MDA-MB-435, PC3, SKBr-3,
Colo205, RPMI8226, SW948, HL-60 and T47D) with the
CDH1 and CDKN2A SMART-MSP assays. Five of these
cell lines were shown to be methylated at the CDH1
promoter at various levels (HL-60: 100%, MDA-MB-435:
75%, PC3: 10%, HS578T: 6% and RPMI8226: 2%).
The ampliﬁcation data (Figure 8A) were used to calculate
the methylation levels as described (see Materials and
methods section). These results were validated using the
CDH1 MethyLight assay, in which the same ﬁve cell lines
were shown to be methylated at similar levels (Figure 8B).
Our results were consistent with previously published data
on these cell lines (28,29).
However, the HS578T cell line was estimated to be
methylated at lower levels when using the MethyLight
assay relative to the SMART-MSP assay. This may be due
to the fact that the probe in the MethyLight assay overlays
two CpGs and that these are not consistently methylated
in this cell line. The melting proﬁles obtained by the
SMART-MSP assay was left-shifted, indicating that at
least one of these two CpGs sites were unmethylated
(data not shown).
Five of the 14 cell lines were shown to be methylated by
SMART-MSP at various levels at the CDKN2A promoter
(T47D: 65%, PC3: 35%, RPMI8226: 30%, Colo205: 1%
and SW948: 0.1%). Again, these results were consistent
with previously published data on these cell lines (28,30).
Screening ofbreast cancer samples
The diagnostic applicability of the SMART-MSP meth-
odology was tested using the RARB and CDH1 assays on
a panel of 24 breast cancer samples. We found 6 out of the
24 samples to be methylated at the RARB promoter region
at levels higher than 5% (76, 57, 44, 33, 29 and 7%). The
ampliﬁcation data (Figure 8C) were used to calculate the
methylation levels. Data from the control assay is not
Figure 4. The quantitative accuracy of the SMART-MSP assays. The quantitative accuracy of the SMART-MSP technology was assessed using the
2
( CT) quantiﬁcation approach. For each assay the calculated gene/control ratio for each standard is plotted against the dilution factor in a double
logarithmic diagram. All assays proved to be quantitatively precise. (A) The CDH1 assay. (B) The DAPK1 assay. (C) The CDKN2A assay.
(D) The RARB assay.
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MethyLight assay, in which the same six samples were
shown to be methylated at similar levels (Figure 8D).
These ﬁndings are in agreement with what has recently
been reported for this locus in breast cancer (31,32).
None of the samples showed high-level methylation
at the CDH1 promoter. We found 11 to be methylated
between 0.1% and 0.7% which could be detected with
high reproducibility. Furthermore, we found 10 samples
to be methylated in the interval from 0.01% to 0.1%, for
which the reproducibility between samples was less good.
These observed values might only account for a biologi-
cally insigniﬁcant background methylation level that
can be found in normal cells (unpublished results).
A recent study has found that a low background of
CDH1 methylation is present in normal breast tissue, and
that this level did not diﬀer signiﬁcantly from what was
found in adjacent malignant breast tissue (32). Another
recent study reports that CDH1 methylation was not
found in a cohort of 28 tissue biopsies from 17 breast
cancer patients (31). However, the method used in that
study was not sensitive enough to detect methylation
levels  1%. Thus, if CDH1 methylation is detected
using a purely qualitative and highly sensitive methodol-
ogy, positive results might arise due to low background
methylation.
We tested the same samples using our CDH1
MethyLight assay with comparable results (data not
shown). However, the CDH1 MethyLight assay was not
able to detect methylation in four of the samples showing
the lowest levels of methylation in the CDH1 SMART-
MSP assay.
DISCUSSION
MSP is a widely used method for the detection of DNA
methylation. It uses primers speciﬁc for methylated (and
optionally unmethylated), bisulphite-modiﬁed DNA (11).
MSP is based on the principle that primers with mis-
matched 30-ends will not be capable of extension during
the PCR. If a band that corresponds to the amplicon size
given by the MSP primers is seen on a gel after PCR, it is
concluded that the sample is methylated. MSP is possibly
Figure 5. Validation of the conversion control in the DAPK1 and
CDKN2A assays. A peripheral blood control sample was bisulphite
treated using diﬀerent times of conversion (20min, 40min, normal
protocol), and used to test the conversion control of these assays.
(A) The DAPK1 assay. A gradual right-shift of the melting peaks was
observed as the treatment time decreases. The observed right-shift of
the incompletely treated samples indicates that some of the non-CpG
cytosines in between the primers were not converted. Thus, these
samples could be identiﬁed as false positives. (B) The CDKN2A assay.
The 40min treated sample and the 20min treated sample both showed
right-shifted melting peaks. Again, indicating that some of non-CpG
cytosines in between the primers were not converted, and thus these
samples could also be identiﬁed as false positives.
Figure 6. Detection of false priming from a whole genome ampliﬁed
template. We used an assay that selected poorly against unmodiﬁed
templates. In this assay, ﬁve non-CpG cytosines and no CpG sites are
found in between the primers. These non-CpG cytosines were converted
to uracil in the bisulphite-modiﬁed template (red), but not in the
unmodiﬁed template (blue). Thus, a signiﬁcant right-shift of the melting
proﬁle of the unmodiﬁed amplicon is observed. (A) Real-time PCR
ampliﬁcation data. (B) First derivative melting peaks.
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and can detect 0.1% methylation or less.
A major drawback of MSP is its susceptibility to false
positives (12–14). This can be due to incomplete conver-
sion of the template, false priming or a sensitivity issue
due to the capacity of MSP to amplify very low-level
methylation.
Incomplete bisulphite conversion is probably the most
problematic cause of false-positive results. When perform-
ing MSP experiments, it is thus important to be conﬁdent
that positive results are not derived from incomplete
conversion. MSP primers are normally designed to have
two or preferably more cytosines deriving from CpG sites
at or near the 30-end. This makes the primers highly
Figure 8. Screening of cell lines for CDH1 methylation and breast cancer samples for RARB methylation. (A) CDH1 SMART-MSP ampliﬁcation
data for the positive cell lines. Five out the 14 cell lines screened were shown to be methylated at the CDH1 promoter. (B) CDH1 MethyLight
ampliﬁcation data from the positive cell lines. The data from the MethyLight assay was consistent with the data from the SMART-MSP assay.
(C) RARB SMART-MSP ampliﬁcation data for the positive tumour samples. Six out the 24 samples screened were shown to be methylated at the
RARB promoter. (D) RARB MethyLight ampliﬁcation data from the positive tumour samples. The data from the MethyLight assay was consistent
with the data from the SMART-MSP assay.
Figure 7. Identiﬁcation of false positives in the CDH1 SMART-MSP assay. The CDH1 SMART-MSP assay was performed with an additional 10
cycles to obtain ampliﬁcation from the unmethylated control (WGA product) shown in green. (A) Real-time PCR ampliﬁcation data. (B) The melting
peak of the fully unmethylated control was left-shifted by  1.28C relative to melting peaks of the standards containing methylated template, and
could thus be identiﬁed as a false-positive result.
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facilitates ampliﬁcation of incomplete converted sequences
in the bisulphite-treated DNA as unconverted sequence
resembles methylated sequence. It is possible that only a
small subset of the DNA copies suﬀer a substantially
lower conversion rate, which in combination with the high
sensitivity of MSP can lead to false positives or over-
estimation of results. Also, it is possible that the
distribution of unconverted sites is non-random, thus
making some promoter regions more prone to incomplete
conversion than others, and that conversion rates are
dependent on DNA quality (16). Thus, in spite of
stringent PCR conditions, a false-positive result can
arise if bisulphite conversion is incomplete. For these
reasons, it is recommended that a control for incomplete
conversion is performed. This control should preferably
assess the conversion status of non-CpG cytosines in the
vicinity of the primer positions. We have shown that
having a non-CpG cytosine at the 30-end is not suﬃcient
to rule out the possible ampliﬁcation of incomplete
converted DNA (Figures 5 and 6).
If the annealing temperature is too low or too many
cycles are used, ampliﬁcation can occur across the 30
mismatch. This type of false positive can be detected by
the use of an appropriate negative control (e.g. WGA
product).
Finally, the sensitivity of MSP might lead to false
positives because of the ampliﬁcation of a rare subpopula-
tion of methylated sequences. The tumour sample might
be extremely heterogeneous, with only a small proportion
of methylated cells. Alternatively, the methylation might
derive from normal cells in the tumour biopsy (12,33).
In either case, it would be incorrect to call the tumour
methylated for that particular gene. This problem arises
because MSP is a non-quantitative methodology. Despite
these limitations, MSP remains useful, particularly
in preliminary screening of a large number of tumour
specimens but may not be suitable in a clinical setting
(7,34).
Here, we have shown that SMART-MSP can give
accurate quantitative data for DNA methylation detec-
tion. The combination of MSP with HRM, which is
enabled by the use of a HRM-compatible DNA double-
stranded intercalating dye, enables the sensitive screening
of the region in between the MSP primers. Thus, infor-
mation is provided that cannot be obtained by electro-
phoresis. For full utility of the methodology, one or both
of two types of primer positioning should be used: (i) only
non-CpG cytosines between the primers allowing assess-
ment if (low) levels of ampliﬁcation are due to incomplete
conversion and (ii) CpGs (with as few non-CpG cytosines
as possible) between the primers allowing assessment
if (low) levels of ampliﬁcation are due to partial or
heterogeneous methylation. Interpretation is made by
considering both the quantiﬁcation and the HRM
information (Figure 1). When the melt proﬁle of a true
positive is established (Figure 2) there is no need for gel
electrophoresis analysis or any further processing, and
thus SMART-MSP is a closed-tube method.
HRM analysis can easily detect single base pair changes
in the ampliﬁed DNA sequence. Thus, by including
non-CpG cytosines between the primers, the conversion
status of these can be assessed. If cytosines in between the
primers are not converted, the amplicons will melt late
relative to amplicons derived from fully converted
template (Figure 1). By generating incompletely converted
DNA sequences, and using these as templates for our
CDKN2A and DAPK1 assays, we were able to show that
ampliﬁcation from these usually occurred, and were easily
identiﬁed as they always corresponded to right-shifted
melting peaks (Figure 5). In addition, we ampliﬁed
unmodiﬁed DNA as well as modiﬁed DNA derived from
the same individual using primers that select poorly
between modiﬁed and unmodiﬁed DNA, and observed
highly reproducible right-shifted melting peaks from
the unmodiﬁed template relative to the modiﬁed one
(Figure 6).
False-positive results due to false priming can be
detected by HRM analysis as well, if CpGs are included
in between the primers (Figure 1). By running the CDH1
SMART-MSP assay for an additional 10 cycles, late
ampliﬁcation from the fully unmethylated control (WGA
product) was seen. In this case, a left-shifted melting peak
was observed due to the two CpGs found in between the
primers being unmethylated. This allowed us to readily
identify it as a false-positive result (Figure 7). However,
suﬃciently stringent PCR conditions and adequate primer
design are the best insurance against false priming.
A left-shifted peak can also be due to the target
sequence being heterogeneously methylated, which can
result in heteroduplex formation, and thus the melting
proﬁle will often be visually diﬀerent (Figure 1). The exact
number of CpG sites that need to be methylated within
MSP primers under given PCR conditions is hard to
assess. This is especially important to keep in mind when
heterogeneously methylated sequences are studied. Thus,
methodologies that utilize MSP primers are only semi-
quantitative when heterogeneously methylated DNA is
ampliﬁed. For this reason, MSP might be less suited in
those cases when CpG islands show highly variable
methylation, as has been reported for the p15INK4B and
CX26 (connexin 26) genes (35–37). However, when
including CpG sites in between the primers in the
SMART-MSP methodology, it can be assessed whether
the studied region is heterogeneously methylated or not,
by the HRM analysis.
We were able to reliably detect the 0.1% methylated
standard for each assay with high reproducibility using
25ng of bisulphite-modiﬁed DNA as template (Figure 3).
Ampliﬁcation from the 0.01% methylated standard was
occasionally observed in all SMART-MSP assays, but
generally showed high run to run variations in CT values.
This might, in part, be caused by very low methylation
levels present in normal blood. However, the quantitative
accuracy in the range from 100% methylated template to
0.1% methylated template was not impaired by the fact
that we did the dilutions in DNA from normal blood.
During WGA of DNA all detectable methylation infor-
mation is lost, and thus it is possible to create fully
unmethylated template. However, results can be biased
during normalization for DNA input if the dilutions are
done using WGA product, since diﬀerent genes are not
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WGA product is excellent as a negative control, especially
when looking at low level methylation.
MSP was originally made quantitative by the use of
TaqMan probes (19–21), but quantiﬁcation without
probes using the dye SYBR Green has been reported
(38–41). SYBR Green intercalation into double-stranded
DNA has been shown to be markedly inﬂuenced by salt
concentration, by dye/base pair ratios which are not
constant during the PCR since more and more double-
stranded DNA is generated through each cycle, and to
show sequence speciﬁc binding (42). For this reason, the
number of PCR cycles can inﬂuence melting curve analysis
(43). Generally, some of the problems associated with
SYBR Green can be minimized if high dye/base pair ratios
are used. However, SYBR Green cannot be used at
saturating concentrations without inhibiting the PCR.
These problems have been markedly reduced by the
introduction of a new generation of dyes (22).
It has previously been shown that melting analysis can
discriminate methylated from unmethylated DNA (44,45).
These assays were based on methylation-independent
PCR (MIP) primers, and have not become widely used,
presumably because of the technical limitations of
reagents, instrumentation and data analysis software
used at that time. Generally, methods utilizing MIP
primers can be compromised by the PCR bias phenom-
enon (46), but this is not an issue when MSP primers
are used.
Melting curve analysis has also been used in combina-
tion with the MSP methodology as an alternative to gel
electrophoresis (47). This methodology did not provide
quantitative data or information that cannot be provided
by gel electrophoresis. Melting analysis of MSP products
in the presence of SYBR green have also been used to
detect primer dimers (38). This can be done by gel
electrophoresis as well. This study did provide quantita-
tive data, but these were much less accurate compared
to what we have obtained with a dye that does not
inhibit PCR.
SMART-MSP is complementary to our previously
described methodology using HRM, methylation-sensitive
HRM (MS-HRM) (48). SMART-MSP uses MSP primers
and quantiﬁcation is based on CT values instead of
melting curve comparisons. Also SMART-MSP can detect
the ampliﬁcation of incompletely converted DNA, and is
generally more sensitive. However, the main advantage
of SMART-MSP might be that each assay is performed
at one annealing temperature; where as in MS-HRM, a
range of diﬀerent temperatures are needed for the sensitive
screening of samples showing markedly diﬀerent methyla-
tion levels. In MS-HRM, quantiﬁcation is based on
comparisons with melting proﬁles of a standard dilution
series that needs to be included in every run. This is not
necessary when performing SMART-MSP assays which
quantify relative to a 100% methylated control and
the ampliﬁcation of a CpG-free control sequence. We
are currently using MS-HRM to analyse samples where
relatively high levels of methylation are expected whereas
SMART-MSP comes into its own to detect low levels
of methylation.
Compared to the MethyLight technology, SMART-
MSP does not require expensive probes. However,
quantiﬁcation without probes is compromised by primer
dimers and non-speciﬁc ampliﬁcation (38). For this
reason, there is a need for evaluation of the PCR product,
which can be conveniently done with HRM analysis.
We observed non-speciﬁc ampliﬁcation from some of
our controls when the assays were performed at lower
annealing temperatures. These products melted diﬀer-
ently, and could be identiﬁed as non-speciﬁc ampliﬁcation
using gel electrophoresis as well (data not shown).
However, when the assays were performed at the
optimized annealing temperature, no primer dimers or
non-speciﬁc products were observed. Without probes, less
optimization may be needed and assay design has become
easier. The use of HRM can give information about the
methylation status of CpGs between the primers, but most
importantly, the HRM step can be used as a control to
indicate ampliﬁcation of incompletely modiﬁed sequences,
false priming or non-speciﬁc products. Thus, SMART-
MSP is less prone to false-positive results and over-
estimation of methylation levels. We have shown that the
sensitivity of our assays is similar to what has been
reported for MethyLight.
In conclusion, SMART-MSP has made quantitative
MSP inexpensive, more accurate, and less prone to false
positives. It is a closed-tube method based on a high-
throughput methodology, and thus it might prove to be
the method of choice for the assessment of DNA methyl-
ation in clinical samples, particularly when low levels
of methylation need to be sensitively and accurately
determined.
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